Studies related to Depression and Marijuana

Cannabinoids In Multiple Sclerosis (CAMS) Study: Safety And Efficacy Data For 12 Months Follow Up

Effect None
Trial Design Cohort
Trial Length 6+ Months
Number of Subjects 502
Sex Both Genders
Age Range 45-64, 65+
Body Types Average
Notes for this study:
Following the completion of the CAMS trial and following up patients who chose to maintain THC / cannabis / placebo treatment for up to a year, it was noted that the benefits towards self-reported muscular health persisted while benefits appeared (to a clinically mild degree) on Ashworth rating scales. Fatigue and Energy, but not irritability or depression, also appeared to be benefited after 27 and 52 weeks.

Full details on all 2 studies are available to Examine Plus members.

Already a member? Login now to access.